Table 3.
Crude and adjusted odds ratios (ORs) of Parkinsonism associated with continuous duration and corresponding dose per day of metoclopramide between cohort entry and index date.
| Metoclopramide use | Case | Control | Crude OR (95% CI) |
Adjusteda
OR (95% CI) |
|---|---|---|---|---|
| Continuous duration | ||||
| No | 256 (47.3) | 2811 (55.3) | 1.00 | 1.00 |
| <1 month | 138 (25.5) | 1321 (26.0) | 1.17 (0.94–1.46) | 1.17 (0.93–1.45) |
| 1–2 months | 50 (9.2) | 391 (7.7) | 1.45 (1.04–2.01) | 1.44 (1.04–2.00) |
| 2–3 months | 28 (5.2) | 177 (3.5) | 1.75 (1.15–2.67) | 1.74 (1.14–2.65) |
| 3–5 months | 27 (5.0) | 169 (3.3) | 1.88 (1.22–2.90) | 1.90 (1.23–2.93) |
| ⩾5 months | 42 (7.8) | 216 (4.3) | 2.18 (1.52–3.14) | 2.17 (1.50–3.12) |
| p for trend | <0.001 | |||
| Dose per day | ||||
| No | 256 (47.3) | 2811 (55.3) | 1.00 | 1.00 |
| <10 mg | 23 (4.3) | 283 (5.6) | 0.91 (0.58–1.42) | 0.90 (0.57–1.40) |
| 10–20 mg | 183 (33.8) | 1426 (28.0) | 1.43 (1.17–1.76) | 1.43 (1.17–1.76) |
| 20–30 mg | 38 (7.0) | 270 (5.3) | 1.59 (1.10–2.29) | 1.57 (1.09–2.26) |
| ⩾30 mg | 41 (7.6) | 295 (5.8) | 1.55 (1.09–2.21) | 1.55 (1.08–2.21) |
| p for trend | <0.001 |
a
Models were adjusted for sex, age, duration from diabetes to index date, hypertension, hyperlipidemia, ever use of statin, and antipsychotics.